Barclays Downgrades Illumina (NASDAQ:ILMN) to Underweight
Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to an “underweight” rating in a research note issued on Monday, Marketbeat.com reports. They currently have a $100.00 target price on the life sciences company’s stock, down from their previous target price of $130.00. Barclays‘s price target […]
